ResMed initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...
My 10 Top Stocks to Buy to Start the New Year Off Right
Investors scored big wins last year as the S&P 500, the Nasdaq, and the Dow Jones Industrial Average all climbed by double ...